Protagenic Therapeutics, Inc.
PTIX
$0.218
-$0.0001-0.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 156.96% | -36.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 151.99% | -60.89% | |||
| Operating Income | -151.99% | 60.89% | |||
| Income Before Tax | -142.46% | 60.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -142.46% | 60.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -142.46% | 60.11% | |||
| EBIT | -151.99% | 60.89% | |||
| EBITDA | -154.98% | 61.35% | |||
| EPS Basic | -77.39% | 60.87% | |||
| Normalized Basic EPS | -86.65% | 62.09% | |||
| EPS Diluted | -77.39% | 60.87% | |||
| Normalized Diluted EPS | -86.65% | 62.09% | |||
| Average Basic Shares Outstanding | 36.70% | 1.93% | |||
| Average Diluted Shares Outstanding | 36.70% | 1.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||